ResearcherNational Cheng Kung University HospitalActive in the last 2 years
Ping‐Jui Su
Matched on ORCID iD 0009-0006-4941-7175; OpenAlex author ID A5033185649. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 12
2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 3 papers · 2026: 2 papers
Papers 7
- Survival benefits of neoadjuvant chemotherapy in advanced pancreatic cancer with vascular resection: who benefits the most? A study on key predictive factors. Co-author DOI 10.1007/s13304-026-02686-8↗
- A decade of progress: a before and after study on improved survival in pancreatic cancer through evolving multimodal therapy. Co-author DOI 10.1097/js9.0000000000005024↗
- Risk Factors and Vascular Features Associated With Local Recurrence in Pancreatic Cancer Post-Pancreaticoduodenectomy: A Retrospective Cohort Study. Co-author DOI 10.1002/cnr2.70267↗
- Outcomes of conversion surgery following chemotherapy for initially unresectable metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study in T… Co-author DOI 10.1007/s00432-025-06353-0↗
- Melanophilin-induced primary cilia promote pancreatic cancer metastasis. Co-author DOI 10.1038/s41419-025-07344-2↗
- The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study. Co-author DOI 10.1097/js9.0000000000000495↗
- Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: a single institution experience. Co-author PMID 35693078↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yan‐Shen Shan · 7 shared papers, 2022–2026 · strength 1.77
- Paper Survival benefits of neoadjuvant chemotherapy in advanced pancreatic cancer with vascular resection: who benefits the m… DOI 10.1007/s13304-026-02686-8↗
- Paper Risk Factors and Vascular Features Associated With Local Recurrence in Pancreatic Cancer Post-Pancreaticoduodenectomy: … DOI 10.1002/cnr2.70267↗
- Paper Outcomes of conversion surgery following chemotherapy for initially unresectable metastatic pancreatic ductal adenocarc… DOI 10.1007/s00432-025-06353-0↗
- Ting‐Kai Liao · 6 shared papers, 2022–2026 · strength 1.53
- Paper Survival benefits of neoadjuvant chemotherapy in advanced pancreatic cancer with vascular resection: who benefits the m… DOI 10.1007/s13304-026-02686-8↗
- Paper Risk Factors and Vascular Features Associated With Local Recurrence in Pancreatic Cancer Post-Pancreaticoduodenectomy: … DOI 10.1002/cnr2.70267↗
- Paper Outcomes of conversion surgery following chemotherapy for initially unresectable metastatic pancreatic ductal adenocarc… DOI 10.1007/s00432-025-06353-0↗
- Ying‐Jui Chao · 3 shared papers, 2022–2025 · strength 0.60
- Paper Outcomes of conversion surgery following chemotherapy for initially unresectable metastatic pancreatic ductal adenocarc… DOI 10.1007/s00432-025-06353-0↗
- Paper The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional st… DOI 10.1097/js9.0000000000000495↗
- Paper Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer… PMID 35693078↗
- Yung‐Yeh Su · 3 shared papers, 2022–2026 · strength 0.57
- Paper A decade of progress: a before and after study on improved survival in pancreatic cancer through evolving multimodal th… DOI 10.1097/js9.0000000000005024↗
- Paper The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional st… DOI 10.1097/js9.0000000000000495↗
- Paper Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer… PMID 35693078↗
- Nai‐Jung Chiang · 2 shared papers, 2022–2023 · strength 0.29
- Paper The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional st… DOI 10.1097/js9.0000000000000495↗
- Paper Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer… PMID 35693078↗
- Chien‐Jui Huang · 2 shared papers, 2022–2023 · strength 0.29
- Paper The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional st… DOI 10.1097/js9.0000000000000495↗
- Paper Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer… PMID 35693078↗
- Li‐Tzong Chen · 2 shared papers, 2022–2023 · strength 0.29
- Paper The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional st… DOI 10.1097/js9.0000000000000495↗
- Paper Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer… PMID 35693078↗
- Chu-An Wang · 1 shared paper, 2025 · strength 0.24
- Chia‐Yih Wang · 1 shared paper, 2025 · strength 0.24
- Yu‐Ying Chao · 1 shared paper, 2025 · strength 0.24
- Shaw‐Jenq Tsai · 1 shared paper, 2025 · strength 0.24
- Hui‐Jen Tsai · 1 shared paper, 2022 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.